<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766270</url>
  </required_header>
  <id_info>
    <org_study_id>CFMD 2016-2-1073</org_study_id>
    <nct_id>NCT02766270</nct_id>
  </id_info>
  <brief_title>CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas</brief_title>
  <official_title>A Prospective Study of Concurrent Chemoradiotherapy With Temozolomide Versus Radiation Therapy Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Neurosurgical Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Shijitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The management of lower-grade gliomas (Diffuse low-grade and intermediate-grade gliomas, WHO
      II and III) is largely based on surgery followed by radiotherapy. Recent studies showed that
      lower-grade glioma patients with IDH wild-type (IDH-wt) and TERT promoter mutation
      (TERTp-mut) had dismal clinical outcomes. These results suggested that current treatment
      strategies are not adequate for this subtype of lower-grade glioma.

      The present study aims to examine the efficacy and safety of concurrent chemoradiotherapy
      with temozolomide followed by adjuvant temozolomide for lower- grade glioma patients with
      IDH-wt and TERTp-mut.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade
      gliomas, World Health Organization grades II and III) are infiltrative neoplasms that arise
      most often in the cerebral hemispheres of adults and include astrocytomas,
      oligodendrogliomas, and oligoastrocytomas. The management of lower-grade gliomas is largely
      based on surgery followed by radiotherapy.

      Lower-grade gliomas have highly variable clinical behavior that is not adequately predicted
      on the basis of histologic class. Consequently, clinicians increasingly rely on genetic
      classification to guide clinical decision making. Mutations in IDH1 and IDH2 characterize the
      majority of lower-grade gliomas in adults and define a subtype that is associated with a
      favorable prognosis. Mutations of the telomerase reverse transcriptase (TERT) promoter, which
      result in enhanced telomerase activity and lengthened telomeres, have been observed in
      several human cancers including glioma. Accumulating evidence suggest that TERT promoter
      mutation is another molecular marker which can stratify lower-grade gliomas into prognostic
      subgroups in combination with IDH mutation. In our previous study, patients(28/377, 7.4%) who
      had lower-grade gliomas with IDH wild-type (IDH-wt) and TERT promoter mutation (TERTp-mut)
      had the poorest clinical outcomes (median OS, 27.7mo; 5-year OS, 29%). These results were
      accordant with the recent studies and suggested that current treatment strategies are not
      adequate for this subtype of lower-grade glioma.

      Radiotherapy plus temozolomide has emerged as a new standard of care for patients with good
      PS non-elderly glioblastoma. There are some data that support temozolomide as adjuvant
      therapy for lower-grade glioma. Given that the IDH-wt/TERTp-mut subgroup of lower-grade
      gliomas has dismal prognosis, a more aggressive therapy such as concurrent chemoradiotherapy
      seems to be reasonable. The present study aims to examine the efficacy and safety of
      concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide for
      lower-grade glioma patients with IDH-wt and TERTp-mut. Half the patients will be randomly
      assigned to receive concurrent chemoradiotherapy (surgery + concurrent chemoradiotherapy with
      temozolomide followed by adjuvant temozolomide) and half the patients will be randomly
      assigned to receive conventional therapy (surgery + radiotherapy only).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Overall survival is defined as the time from randomization to death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Progression free survival(PFS) is defined as the time from randomization to progressive disease or death. A combination of neurological examination and MRI brain scan used to define progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events associated with treatment with RT alone and combined with temozolomide chemotherapy; according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0.</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Grade II/III Glioma</condition>
  <arm_group>
    <arm_group_label>Chemoradiotherapy with Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy) and receive temozolomide PO QD (75 mg/m2/day, 7 days/week) for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5 (150-200 mg/m2). Treatment with temozolomide repeats every 28 days for up to 12 courses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>RT with daily temozolomide (75 mg/m2/day, 7 days/week for up to 7 weeks) and adjuvant temozolomide (150-200 mg/m2 PO QD for 5 days, repeats every 28 days for up to 12 courses).</description>
    <arm_group_label>Chemoradiotherapy with Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Chemoradiotherapy with Temozolomide</arm_group_label>
    <arm_group_label>Radiotherapy alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed supratentorial Diffuse low-grade and intermediate-grade
             gliomas (World Health Organization grades II and III )

          -  IDH wild-type and TERT promoter mutation

          -  Age &gt; 18

          -  Karnofsky performance score &gt; 60

          -  Neutrophilic granulocyte count &gt; 1500/µl

          -  Platelet count &gt; 100 000/µl

          -  Hemoglobin &gt; 10 g/dl

          -  Serum creatinine &lt; 1.5 times the lab's upper normal limit

          -  AST or ALT &lt; 1.5 times the lab's upper normal limit

          -  Adequate medical health to participate in this study

          -  No previous systemic chemotherapy

          -  No previous radiotherapy to the brain

          -  Written informed consent

        Exclusion Criteria:

          -  Serious medical or neurological condition with a poor prognosis

          -  Contraindications to radiotherapy or temozolomide chemotherapy

          -  Patient unable to follow procedures, visits, examinations described in the study

          -  Second cancer requiring radiotherapy or chemotherapy

          -  Inability to undergo gadolinium-contrasted MRIs

          -  Pregnant women or nursing mothers can not participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Jiang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-Guang Qiu, M.D.</last_name>
    <phone>0086-010-67096611</phone>
    <email>ttyy6611@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao-Guang Qiu, M.D.</last_name>
      <email>ttyy6611@126.com</email>
    </contact>
    <investigator>
      <last_name>Tao Jiang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765-73. doi: 10.1056/NEJMoa0808710.</citation>
    <PMID>19228619</PMID>
  </reference>
  <reference>
    <citation>Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008 Sep 26;321(5897):1807-12. doi: 10.1126/science.1164382. Epub 2008 Sep 4.</citation>
    <PMID>18772396</PMID>
  </reference>
  <reference>
    <citation>Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IeM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6. doi: 10.1073/pnas.1303607110. Epub 2013 Mar 25.</citation>
    <PMID>23530248</PMID>
  </reference>
  <reference>
    <citation>Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. 2013 Dec;126(6):931-7. doi: 10.1007/s00401-013-1163-0. Epub 2013 Aug 17.</citation>
    <PMID>23955565</PMID>
  </reference>
  <reference>
    <citation>Yang P, Cai J, Yan W, Zhang W, Wang Y, Chen B, Li G, Li S, Wu C, Yao K, Li W, Peng X, You Y, Chen L, Jiang C, Qiu X, Jiang T; CGGA project. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Neuro Oncol. 2016 Aug;18(8):1099-108. doi: 10.1093/neuonc/now021. Epub 2016 Mar 7.</citation>
    <PMID>26957363</PMID>
  </reference>
  <reference>
    <citation>Chan AK, Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, Shi Z, Chan DT, Poon WS, Zhou L, Ng HK. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Mod Pathol. 2015 Feb;28(2):177-86. doi: 10.1038/modpathol.2014.94. Epub 2014 Aug 1.</citation>
    <PMID>25081751</PMID>
  </reference>
  <reference>
    <citation>Labussière M, Di Stefano AL, Gleize V, Boisselier B, Giry M, Mangesius S, Bruno A, Paterra R, Marie Y, Rahimian A, Finocchiaro G, Houlston RS, Hoang-Xuan K, Idbaih A, Delattre JY, Mokhtari K, Sanson M. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer. 2014 Nov 11;111(10):2024-32. doi: 10.1038/bjc.2014.538. Epub 2014 Oct 14.</citation>
    <PMID>25314060</PMID>
  </reference>
  <reference>
    <citation>Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.</citation>
    <PMID>19269895</PMID>
  </reference>
  <reference>
    <citation>Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE 2nd, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003 Feb 15;21(4):646-51.</citation>
    <PMID>12586801</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2016</study_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Tao Jiang</investigator_full_name>
    <investigator_title>Vice Director of Neurosurgical Department</investigator_title>
  </responsible_party>
  <keyword>Grade II/III Glioma</keyword>
  <keyword>IDH</keyword>
  <keyword>TERT</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Temozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

